31R Stock Chart & Stats
€0.03
€0.01(62.50%)
At close: 4:00 PM EDT
€0.03
€0.01(62.50%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.06
Previous CloseN/A
Volume3.00K
Average Volume (3M)15.15K
Market Cap
€6.47M
Enterprise Value€13.12M
Total Cash (Recent Filing)€22.66K
Total Debt (Recent Filing)€70.77K
Price to Earnings (P/E)―
Beta-23.89
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding418,564,270
10 Day Avg. Volume21,703
30 Day Avg. Volume15,152
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute DebtVery low absolute debt reduces interest burden and near-term solvency risk for a pre-revenue R&D firm. This durable capital structure feature preserves optionality to pursue clinical programs without fixed debt repayments, easing short-term liquidity pressure while seeking financing.
Focused R&D PipelineA clear, specialty drug-development focus (psilocybin and repurposed compounds) concentrates resources on differentiated therapeutic niches. Over months, disciplined R&D programs and potential intellectual property are durable drivers of future commercialization and licensing or partnership opportunities.
Improved Cash Outflow TrendMeaningful reduction in operating cash outflows versus prior periods indicates improved cost control or program re-phasing. If sustained, lower burn materially extends runway, reduces near-term financing needs and dilution risk, strengthening the company’s ability to advance clinical milestones.
Bears Say
No Revenue / No CommercializationThe company remains entirely pre-revenue with negative gross profit, signaling no commercialization to absorb R&D and G&A costs. This structural lack of cash-generating operations makes long-term viability dependent on successful clinical outcomes or external financing, a persistent risk.
Negative Shareholders' EquityNegative shareholders’ equity reflects accumulated losses and weakened balance sheet flexibility. Over months this constrains financing options, can lead to more dilutive capital raises or restrictive covenants, and signals an erosion of the firm's financial buffer against adverse outcomes.
Persistent Negative Cash Flow / Financing DependenceConsistent negative operating and free cash flow forces reliance on external capital to fund operations. This structural financing dependence increases dilution risk, narrows strategic choices, and makes progress contingent on successful raises or partnerships rather than internal cash generation.
Revive Therapeutics News
31R FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <€0.01 and its highest was €0.06 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is €6.47M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is Oct 26, 2026 which is in 84 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Revive Therapeutics Ltd released its earnings results on Jun 01, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Revive Therapeutics Ltd reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in DE:31R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.